Experience of a Multidisciplinary Task Force with Exome Sequencing for Mendelian Disorders

Overview

Journal Hum Genomics

Publisher Biomed Central

Specialty Genetics

Date 2016 Jun 30

PMID 27353043

Citations 20

Authors

S Fokstuen

P Makrythanasis

E Hammar

M Guipponi

E Ranza

K Varvagiannis

F A Santoni

M Albarca-Aguilera

M E Poleggi

F Couchepin

C Brockmann

A Mauron

S A Hurst

C Moret

C Gehrig

A Vannier

J Bevillard

T Araud

S Gimelli

E Stathaki

A Paoloni-Giacobino

A Bottani

F Sloan-Bena

L DAmato Sizonenko

M Mostafavi

H Hamamy

T Nouspikel

J L Blouin

S E Antonarakis

Affiliations

Soon will be listed here.

Abstract

Background: In order to optimally integrate the use of high-throughput sequencing (HTS) as a tool in clinical diagnostics of likely monogenic disorders, we have created a multidisciplinary "Genome Clinic Task Force" at the University Hospitals of Geneva, which is composed of clinical and molecular geneticists, bioinformaticians, technicians, bioethicists, and a coordinator.

Methods And Results: We have implemented whole exome sequencing (WES) with subsequent targeted bioinformatics analysis of gene lists for specific disorders. Clinical cases of heterogeneous Mendelian disorders that could potentially benefit from HTS are presented and discussed during the sessions of the task force. Debate concerning the interpretation of identified variants and the content of the final report constitutes a major part of the task force's work. Furthermore, issues related to bioethics, genetic counseling, quality control, and reimbursement are also addressed.

Conclusions: This multidisciplinary task force has enabled us to create a platform for regular exchanges between all involved experts in order to deal with the multiple complex issues related to HTS in clinical practice and to continuously improve the diagnostic use of HTS. In addition, this task force was instrumental to formally approve the reimbursement of HTS for molecular diagnosis of Mendelian disorders in Switzerland.

Citing Articles

Identification of a novel likely pathogenic TPM1 variant linked to hypertrophic cardiomyopathy in a family with sudden cardiac death.

Azimi A, Soveizi M, Salmanipour A, MozafaryBazargany M, Ghaffari Jolfayi A, Maleki M ESC Heart Fail. 2024; 11(5):3180-3190.

PMID: 38874371 PMC: 11424302. DOI: 10.1002/ehf2.14906.

Implementing evidence-based assertions of clinical actionability in the context of secondary findings: Updates from the ClinGen Actionability Working Group.

Pak C, Gilmore M, Bulkley J, Chakraborty P, Dagan-Rosenfeld O, Foreman A Genet Med. 2024; 26(8):101164.

PMID: 38757444 PMC: 11298308. DOI: 10.1016/j.gim.2024.101164.

Exploring TTN variants as genetic insights into cardiomyopathy pathogenesis and potential emerging clues to molecular mechanisms in cardiomyopathies.

Ghaffari Jolfayi A, Kohansal E, Ghasemi S, Naderi N, Hesami M, MozafaryBazargany M Sci Rep. 2024; 14(1):5313.

PMID: 38438525 PMC: 10912352. DOI: 10.1038/s41598-024-56154-7.

Combining globally search for a regular expression and print matching lines with bibliographic monitoring of genomic database improves diagnosis.

Mau-Them F, Overs A, Bruel A, Duquet R, Thareau M, Denomme-Pichon A Front Genet. 2023; 14:1122985.

PMID: 37152996 PMC: 10157399. DOI: 10.3389/fgene.2023.1122985.

A Multi-Disciplinary Team Approach to Genomic Testing for Drug-Resistant Epilepsy Patients-The GENIE Study.

Vadlamudi L, Bennett C, Tom M, Abdulrasool G, Brion K, Lundie B J Clin Med. 2022; 11(14).

PMID: 35888005 PMC: 9319736. DOI: 10.3390/jcm11144238.

References

Matthijs G, Souche E, Alders M, Corveleyn A, Eck S, Feenstra I . Guidelines for diagnostic next-generation sequencing. Eur J Hum Genet. 2015; 24(1):2-5. PMC: 4795226. DOI: 10.1038/ejhg.2015.226. View

Plon S, Eccles D, Easton D, Foulkes W, Genuardi M, Greenblatt M . Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008; 29(11):1282-91. PMC: 3075918. DOI: 10.1002/humu.20880. View

Metzker M . Sequencing technologies - the next generation. Nat Rev Genet. 2009; 11(1):31-46. DOI: 10.1038/nrg2626. View

Sun Y, Ruivenkamp C, Hoffer M, Vrijenhoek T, Kriek M, van Asperen C . Next-generation diagnostics: gene panel, exome, or whole genome?. Hum Mutat. 2015; 36(6):648-55. DOI: 10.1002/humu.22783. View

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N . The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078-9. PMC: 2723002. DOI: 10.1093/bioinformatics/btp352. View

Makrythanasis P, Antonarakis S . High-throughput sequencing and rare genetic diseases. Mol Syndromol. 2013; 3(5):197-203. PMC: 3531930. DOI: 10.1159/000343941. View

MacArthur D, Manolio T, Dimmock D, Rehm H, Shendure J, Abecasis G . Guidelines for investigating causality of sequence variants in human disease. Nature. 2014; 508(7497):469-76. PMC: 4180223. DOI: 10.1038/nature13127. View

Rehm H, Bale S, Bayrak-Toydemir P, Berg J, Brown K, Deignan J . ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013; 15(9):733-47. PMC: 4098820. DOI: 10.1038/gim.2013.92. View

Deverka P, Kaufman D, McGuire A . Overcoming the reimbursement barriers for clinical sequencing. JAMA. 2014; 312(18):1857-8. PMC: 5087268. DOI: 10.1001/jama.2014.14915. View

10.

Ye K, Schulz M, Long Q, Apweiler R, Ning Z . Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009; 25(21):2865-71. PMC: 2781750. DOI: 10.1093/bioinformatics/btp394. View

11.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

12.

Biesecker L . Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med. 2012; 14(4):393-8. PMC: 3790899. DOI: 10.1038/gim.2011.78. View

13.

Lee H, Deignan J, Dorrani N, Strom S, Kantarci S, Quintero-Rivera F . Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014; 312(18):1880-7. PMC: 4278636. DOI: 10.1001/jama.2014.14604. View

14.

Marx A, Hoenger A, Mandelkow E . Structures of kinesin motor proteins. Cell Motil Cytoskeleton. 2009; 66(11):958-66. PMC: 2765580. DOI: 10.1002/cm.20392. View

15.

Ayuso C, Millan J, Mancheno M, Dal-Re R . Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process. Eur J Hum Genet. 2013; 21(10):1054-9. PMC: 3778336. DOI: 10.1038/ejhg.2012.297. View

16.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

17.

Ng S, Buckingham K, Lee C, Bigham A, Tabor H, Dent K . Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2009; 42(1):30-5. PMC: 2847889. DOI: 10.1038/ng.499. View

18.

Linderman M, Brandt T, Edelmann L, Jabado O, Kasai Y, Kornreich R . Analytical validation of whole exome and whole genome sequencing for clinical applications. BMC Med Genomics. 2014; 7:20. PMC: 4022392. DOI: 10.1186/1755-8794-7-20. View

19.

Green R, Berg J, Grody W, Kalia S, Korf B, Martin C . ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15(7):565-74. PMC: 3727274. DOI: 10.1038/gim.2013.73. View